Analyzing Protalix BioTherapeutics (NYSE:PLX) & Pharming Group (NASDAQ:PHAR)

Pharming Group (NASDAQ:PHAR – Get Free Report) and Protalix BioTherapeutics (NYSE:PLX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Volatility and Risk

Pharming Group has a beta of -0.05, suggesting that its stock price is 105% less volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500.

Institutional and Insider Ownership

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Pharming Group and Protalix BioTherapeutics”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pharming Group $386.75 million 2.30 $2.85 million $0.32 39.34
Protalix BioTherapeutics $84.69 million 3.00 $8.31 million $0.25 12.04

Protalix BioTherapeutics has lower revenue, but higher earnings than Pharming Group. Protalix BioTherapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Pharming Group and Protalix BioTherapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharming Group 0 2 3 0 2.60
Protalix BioTherapeutics 0 0 1 0 3.00

Pharming Group currently has a consensus price target of $39.67, indicating a potential upside of 215.06%. Protalix BioTherapeutics has a consensus price target of $12.00, indicating a potential upside of 298.67%. Given Protalix BioTherapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Pharming Group.

Profitability

This table compares Pharming Group and Protalix BioTherapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pharming Group 6.23% 8.70% 4.93%
Protalix BioTherapeutics -21.03% -30.89% -11.74%

About Pharming Group

(Get Free Report)

Pharming Group N.V. is a biotechnology company headquartered in Leiden, the Netherlands, that develops and commercializes medicines for rare and underserved diseases. Founded in 1988, the company has built its business around treatments for disorders involving the immune system. Its marketed products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).

About Protalix BioTherapeutics

(Get Free Report)

Protalix BioTherapeutics is an Israel-based biopharmaceutical company that develops and manufactures recombinant therapeutic proteins using its proprietary plant-cell expression system, ProCellEx. The company focuses on treatments for rare and chronic diseases and was founded in 1993. Its products include Elelyso (taliglucerase alfa), an enzyme replacement therapy for Gaucher disease, and Elfabrio (pegunigalsidase alfa), an enzyme replacement therapy for Fabry disease. Protalix developed Elfabrio in collaboration with Chiesi Global Rare Diseases; commercialization and distribution are handled through partner arrangements in multiple markets.

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.